Jiangsu Hengrui Medicine Co.,Ltd.
Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.
Ms. Linda Zhao
Head, US BD TeamJiangsu Hengrui Pharma
Hengrui is the largest pharmaceutical company based in China by market cap (around 90 billion USD) and among the top ones by revenue and R&D spending (3.28b USD and 549m USD in 2019, respectively). 5+ differentiated products in global clinical development with commercial rights available for discussions.
Dr. Duan Wang
Associate Director of BDJianlian Group
Jianmin Group is a integrated pharmaceutical company with a major focus on pediatric product development manufacturing, and marketing.
平 郭
BDJianmin Pharma Group
Jianmin Group (600976.SSE) is an integrated pharmaceutical company with a major focus on pediatric product development, manufacture, and marketing. Founded in 1953, headquartered in Wuhan, the largest city in Central China, its history can be traced back to 17th century. Jianmin has been a famous pharma brand in China among children and their parents for generations. Its rich pediatric portfolio ranges from nutrition, hematology, respiratory, digestive, CNS, to infections and common cold as well.
Mr Wei Li
Head of Business DevelopmentJIAYUHONGDE INVESTMENT (SHANGHAI)Ltd
Investment management company commits to authentic relationships, communications, and promises,builds productive operations and profitable businesses,invests in the field of medical technology, new energy source etc.